ENGN vs. AVBP, SIBN, ORIC, VREX, SLN, PHAT, PACB, SVRA, ZYME, and MLAB
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include ArriVent BioPharma (AVBP), SI-BONE (SIBN), ORIC Pharmaceuticals (ORIC), Varex Imaging (VREX), Silence Therapeutics (SLN), Phathom Pharmaceuticals (PHAT), Pacific Biosciences of California (PACB), Savara (SVRA), Zymeworks (ZYME), and Mesa Laboratories (MLAB). These companies are all part of the "medical" sector.
enGene (NASDAQ:ENGN) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
enGene presently has a consensus target price of $34.40, indicating a potential upside of 165.02%. ArriVent BioPharma has a consensus target price of $29.25, indicating a potential upside of 45.52%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than ArriVent BioPharma.
64.2% of enGene shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, enGene had 32 more articles in the media than ArriVent BioPharma. MarketBeat recorded 38 mentions for enGene and 6 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.94 beat enGene's score of -0.05 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
enGene and ArriVent BioPharma both received 7 outperform votes by MarketBeat users.
Summary
enGene beats ArriVent BioPharma on 6 of the 8 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
